The preclinical phase of AD is prolonged, with tau lesions and associated neuronal loss first appearing in the subcortical nuclei, followed by cognitive decline and neuropsychiatric symptoms in the limbic regions as the disease progresses. This evidence concerns the gene MAPT and Alzheimer disease.